| Dr Phat Van Du, PHARMD | |
|
11401 Bloomfield Ave, Norwalk, CA 90650-2015 | |
| (562) 651-5439 | |
| (562) 863-2664 |
| Full Name | Dr Phat Van Du |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 11401 Bloomfield Ave, Norwalk, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154859809 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 51011 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Phat Van Du, PHARMD 11401 Bloomfield Ave, Norwalk, CA 90650-2015 Ph: () - | Dr Phat Van Du, PHARMD 11401 Bloomfield Ave, Norwalk, CA 90650-2015 Ph: (562) 651-5439 |
News Archive
Traditionally, Public Relations has served as a limited marketing tool for generating brand awareness and reaching consumers. More recently, the reach and potential of Public Relations has greatly expanded through technologies such as Web sites, online social networks, information alerts and blogs. Meanwhile, traditional media sources continue to play an important role.
Personal Genome Diagnostics, Inc., a leader in cancer genomics and pioneer in liquid biopsy, today reported that its non-invasive, pan-cancer plasma assay is being used in an important new clinical trial, Nivolumab, Ipilimumab in Patients With Hyper Mutated Cancers Detected in Blood, led by the Cancer Research Institute and Canadian Cancer Trials Group.
Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor EDURANT tablets versus efavirenz (EFV) in antiretroviral treatment-naive, HIV-1-infected adults.
An analysis of previous studies indicates that among patients with peripheral artery disease, aspirin use is associated with a statistically nonsignificant decrease in the risk of a group of combined cardiovascular events (nonfatal heart attack, nonfatal stroke, and cardiovascular death), but is associated with a significant reduction in the risk of one of these events, nonfatal stroke, although the findings may be limited by the lack of a large study population, according to an article in the May 13 issue of JAMA, the Journal of the American Medical Association.
› Verified 8 days ago
Dr. Peter Ka Hou Cheong, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12051 Imperial Hwy, Norwalk, CA 90650 Phone: 562-484-9849 | |
Hyung Kim, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12519 Alondra Blvd, Norwalk, CA 90650 Phone: 562-921-9481 | |
Hayeon Chi, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 11930 Studebaker Rd, Norwalk, CA 90650 Phone: 562-864-8138 | |
Dr. William H Diamant, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 11930 Studebaker Rd, Norwalk, CA 90650 Phone: 562-864-8138 Fax: 562-929-8489 | |
Abanoub Akhnoukh, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 11011 Alondra Blvd, Norwalk, CA 90650 Phone: 562-864-2427 | |
Mairyana George Boulos, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 14427 Grayland Ave, Norwalk, CA 90650 Phone: 562-900-1556 | |
Stuart Koizumi, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10968 Rosecrans Ave., Norwalk, CA 90650 Phone: 562-462-9256 |